I don't know where you got the number of 40% successful in PIII. I have been in biotech for more than ten years and have seen only a very limited PIII successes. Less than 20% is the accurate number. This is why we have only a handful profitable biotech companies instead of hundreds, while vast majority like MYGN either failed or will fail.
The whole market is going down currently. MYGN will fall back sharply. Be careful now.